ZA975064B - Polymorphs of donepezil hydrochloride and process for production. - Google Patents
Polymorphs of donepezil hydrochloride and process for production.Info
- Publication number
- ZA975064B ZA975064B ZA9705064A ZA975064A ZA975064B ZA 975064 B ZA975064 B ZA 975064B ZA 9705064 A ZA9705064 A ZA 9705064A ZA 975064 A ZA975064 A ZA 975064A ZA 975064 B ZA975064 B ZA 975064B
- Authority
- ZA
- South Africa
- Prior art keywords
- polymorphs
- donepezil hydrochloride
- production
- peaks
- hydrochloride
- Prior art date
Links
- 229960003135 donepezil hydrochloride Drugs 0.000 title abstract 2
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 title abstract 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 abstract 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 238000000862 absorption spectrum Methods 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14629396 | 1996-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA975064B true ZA975064B (en) | 1998-04-01 |
Family
ID=15404413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA9705064A ZA975064B (en) | 1996-06-07 | 1997-06-09 | Polymorphs of donepezil hydrochloride and process for production. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6140321A (de) |
| JP (2) | JP2005015486A (de) |
| KR (1) | KR100545851B1 (de) |
| CN (1) | CN1312129C (de) |
| AT (1) | ATE445603T1 (de) |
| AU (1) | AU1153097A (de) |
| CA (1) | CA2516108C (de) |
| DE (1) | DE69739622D1 (de) |
| DK (1) | DK1211243T3 (de) |
| ES (1) | ES2330997T3 (de) |
| HU (1) | HUP0900417A3 (de) |
| PT (1) | PT1211243E (de) |
| SI (1) | SI22888B (de) |
| UA (1) | UA60307C2 (de) |
| WO (1) | WO1997046526A1 (de) |
| ZA (1) | ZA975064B (de) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0004331A3 (en) | 1997-08-21 | 2001-09-28 | Gerolymatos P N Sa | Use of phanquinone for producing pharmaceutical compositions for the treatment of alzheimer's disease and combined pharmaceutical compositions containing it |
| CA2304505A1 (en) * | 1997-09-24 | 1999-04-01 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
| WO2000040244A1 (en) | 1999-01-07 | 2000-07-13 | P.N. Gerolymatos S.A. | Use of phanquinone for the treatment or prevention of memory impairment |
| WO2000051985A1 (en) * | 1999-03-03 | 2000-09-08 | Eisai Co., Ltd. | Fluorides of 4-substituted piperidine derivatives |
| US20060183776A9 (en) * | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
| EP1311272B1 (de) | 2000-03-03 | 2006-11-22 | Eisai Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| US20040034057A1 (en) * | 2000-09-25 | 2004-02-19 | Akio Imai | Process for producing multiform crystal of donepezil hydrochloride |
| US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
| US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
| US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
| US20050249786A1 (en) * | 2001-09-28 | 2005-11-10 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds |
| US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
| US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
| US20050142088A1 (en) * | 2002-02-07 | 2005-06-30 | Mitsuru Mizuno | Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
| WO2003093324A1 (en) * | 2002-05-01 | 2003-11-13 | San-Ei Gen F.F.I., Inc. | Method of modifying gum arabic |
| IL150509A (en) | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US20060014801A1 (en) * | 2002-11-22 | 2006-01-19 | The Johns Hopkins University | Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs |
| IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US20050288330A1 (en) * | 2004-06-29 | 2005-12-29 | Avinash Naidu | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7560560B2 (en) * | 2003-04-16 | 2009-07-14 | Hetero Drugs Limited | Crystalline forms of donepezil hydrochloride |
| WO2004099142A1 (en) * | 2003-05-05 | 2004-11-18 | Ranbaxy Laboratories Limited | Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2005065645A2 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| TW200533371A (en) * | 2004-04-15 | 2005-10-16 | Dainippon Pharmaceutical Co | Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative |
| AU2005244867A1 (en) * | 2004-05-14 | 2005-12-01 | The Johns Hopkins University | Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor |
| WO2006015338A2 (en) * | 2004-07-30 | 2006-02-09 | Dr. Reddy's Laboratories Ltd. | Crystalline form of donepezil hydrochloride |
| US7371906B2 (en) * | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| US7592459B2 (en) * | 2004-09-29 | 2009-09-22 | Chemagis Ltd. | Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride |
| KR101381454B1 (ko) * | 2004-09-29 | 2014-04-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트 |
| ATE415148T1 (de) * | 2004-10-19 | 2008-12-15 | Krka Tovarna Zdravil D D Novo | Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| WO2006056845A1 (en) * | 2004-11-23 | 2006-06-01 | Warner-Lambert Company Llc | 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia |
| US20060122226A1 (en) * | 2004-12-08 | 2006-06-08 | Itai Adin | Crystalline forms of Donepezil base |
| EP1827468B1 (de) * | 2004-12-23 | 2012-08-22 | Curaxis Pharmaceutical Corporation | Acetylcholinesterasehemmer und Leuprolidacetat zur Behandlung von Alzheimer-Krankheit |
| US20060270709A1 (en) * | 2005-04-04 | 2006-11-30 | Eisai Co. Ltd. | Dihydropyridine compounds and compositions for headaches |
| US20070026075A1 (en) * | 2005-07-28 | 2007-02-01 | Jutaro Shudo | Gelled donepezil compositions and methods for making and using the same |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| US7274339B2 (en) * | 2005-09-16 | 2007-09-25 | Smartant Telecom Co., Ltd. | Dual-band multi-mode array antenna |
| DE102005060377A1 (de) * | 2005-12-16 | 2007-06-21 | Ratiopharm Gmbh | Pharmazeutische Zusammensetzung enthaltend Donepezilhydrochlorid, Tablette hieraus und Verfahren zu deren Herstellung |
| HU227474B1 (en) * | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
| WO2007108011A2 (en) * | 2006-03-20 | 2007-09-27 | Ind-Swift Laboratories Limited | Process for the preparation of highly pure donepezil |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (de) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Zusammensetzungen von DPP-IV-Inhibitoren |
| JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2008117123A2 (en) * | 2006-10-16 | 2008-10-02 | Medichem, S.A. | Process for preparing donepezil hydrochloride polymorphic form i |
| AU2007309390A1 (en) | 2006-10-27 | 2008-05-02 | Medivation Neurology, Inc. | Methods and combination therapies for treating Alzheimer's disease |
| CA2668748A1 (en) * | 2006-11-09 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
| US20100113533A1 (en) * | 2006-11-14 | 2010-05-06 | Bayer Schering Pharma Aktiengesellschaft | Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide |
| US20100099714A1 (en) * | 2007-03-05 | 2010-04-22 | Eisai R&D Management Co., Ltd. | AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases |
| EP2148673A1 (de) * | 2007-04-26 | 2010-02-03 | Eisai R&D Management Co., Ltd. | Cinnamid-verbindungen gegen demenz |
| WO2009084030A2 (en) * | 2007-12-03 | 2009-07-09 | Neuland Laboratories Ltd. | Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP5488956B2 (ja) * | 2008-11-25 | 2014-05-14 | 株式会社Ｄｎｐファインケミカル宇都宮 | （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩のＩ形結晶とＩＩ形結晶の混晶の製造法 |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| WO2011061591A1 (en) | 2009-11-18 | 2011-05-26 | Jubilant Life Sciences Limited | Improved process for the preparation of 1-benzyl-4-(5,6-dimethoxy-1-indanone)-2-yl)methyl piperidine hydrochloride form-iii |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| IT1397912B1 (it) * | 2010-01-28 | 2013-02-04 | Chemi Spa | Nuovo polimorfo dell'estere 6-dietilamminometil-2-naftilico dell'acido 4-idrossicarbamoil-fenil-carbammico cloridrato. |
| EA202092673A3 (ru) | 2010-02-09 | 2021-05-31 | Дзе Джонс Хопкинс Юниверсити | Способы и композиции для улучшения когнитивной функции |
| EP2366378A1 (de) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Donepezilformulierungen mit verzögerter Freisetzung |
| US20110251239A1 (en) | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
| NZ602872A (en) * | 2010-04-07 | 2014-05-30 | Onyx Therapeutics Inc | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| WO2012053016A1 (en) | 2010-10-22 | 2012-04-26 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| CN103012247B (zh) * | 2013-01-18 | 2014-12-10 | 浙江东亚药业有限公司 | 一种盐酸多奈哌齐无水i晶型的制备方法 |
| CN103965188A (zh) * | 2013-01-29 | 2014-08-06 | 中山大学 | 含硒多奈哌齐类似物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| AU2014228512A1 (en) | 2013-03-15 | 2015-10-01 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| AU2014307803A1 (en) | 2013-08-16 | 2016-03-10 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| EP3110449B1 (de) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medizinische verwendung eines dpp-4-inhibitors |
| CA2986598C (en) | 2015-05-22 | 2023-09-26 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
| EP4233840A3 (de) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Kombinationen aus linagliptin und metformin |
| CN106397306B (zh) * | 2016-10-20 | 2019-03-08 | 山东罗欣药业集团股份有限公司 | 一种盐酸多奈哌齐晶型化合物及其制备方法 |
| US10369187B2 (en) | 2017-02-09 | 2019-08-06 | Vanderbilt University | Peptide regulators of JNK family kinases |
| PT3843702T (pt) | 2019-05-31 | 2023-10-13 | Tecnimede Soc Tecnico Medicinal Lda | Combinação de dose fixa de libertação imediata de memantina e donepezilo |
| EP4642432A1 (de) | 2022-12-28 | 2025-11-05 | Corium, LLC | Vormischungsverfahren zur herstellung eines transdermalen abgabesystems |
| JP2025542470A (ja) | 2022-12-28 | 2025-12-25 | コリウム， エルエルシー | 経皮送達システムを調製する方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
-
1996
- 1996-12-27 AU AU11530/97A patent/AU1153097A/en not_active Abandoned
- 1996-12-27 WO PCT/JP1996/003881 patent/WO1997046526A1/en not_active Ceased
- 1996-12-30 US US08/774,802 patent/US6140321A/en not_active Expired - Fee Related
-
1997
- 1997-06-06 SI SI9720102A patent/SI22888B/sl not_active IP Right Cessation
- 1997-06-06 CN CNB200510075915XA patent/CN1312129C/zh not_active Expired - Fee Related
- 1997-06-06 KR KR1020047017860A patent/KR100545851B1/ko not_active Expired - Fee Related
- 1997-06-06 UA UA99010107A patent/UA60307C2/uk unknown
- 1997-06-06 ES ES02005248T patent/ES2330997T3/es not_active Expired - Lifetime
- 1997-06-06 DK DK02005248.6T patent/DK1211243T3/da active
- 1997-06-06 HU HU0900417A patent/HUP0900417A3/hu unknown
- 1997-06-06 PT PT02005248T patent/PT1211243E/pt unknown
- 1997-06-06 DE DE69739622T patent/DE69739622D1/de not_active Expired - Lifetime
- 1997-06-06 CA CA002516108A patent/CA2516108C/en not_active Expired - Fee Related
- 1997-06-06 AT AT02005248T patent/ATE445603T1/de active
- 1997-06-09 ZA ZA9705064A patent/ZA975064B/xx unknown
-
2004
- 2004-07-12 JP JP2004205012A patent/JP2005015486A/ja active Pending
-
2008
- 2008-08-04 JP JP2008201060A patent/JP2009040783A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005015486A (ja) | 2005-01-20 |
| JP2009040783A (ja) | 2009-02-26 |
| SI22888A (sl) | 2010-04-30 |
| AU1153097A (en) | 1998-01-05 |
| CN1312129C (zh) | 2007-04-25 |
| WO1997046526A1 (en) | 1997-12-11 |
| DE69739622D1 (de) | 2009-11-26 |
| KR100545851B1 (ko) | 2006-01-24 |
| PT1211243E (pt) | 2009-11-06 |
| DK1211243T3 (da) | 2010-02-08 |
| ATE445603T1 (de) | 2009-10-15 |
| KR20040104707A (ko) | 2004-12-10 |
| CA2516108C (en) | 2008-12-02 |
| CN1699343A (zh) | 2005-11-23 |
| HU0900417D0 (en) | 2009-08-28 |
| SI22888B (sl) | 2010-06-30 |
| UA60307C2 (uk) | 2003-10-15 |
| CA2516108A1 (en) | 1997-12-11 |
| HK1080078A1 (en) | 2006-04-21 |
| HUP0900417A3 (en) | 2012-12-28 |
| US6140321A (en) | 2000-10-31 |
| ES2330997T3 (es) | 2009-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA975064B (en) | Polymorphs of donepezil hydrochloride and process for production. | |
| CA2252806A1 (en) | Polymorphs of donepezil hydrochloride and process for production | |
| HUP0003141A3 (en) | 4-phenylpiperidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| HU903852D0 (en) | Process for producing zirconium dioxide based fire-proof materials | |
| HUP9802762A3 (en) | Diphenylmethylene piperidine derivatives, pharmaceutical compositions containing them, process for producing them and their use | |
| HRP960592A2 (en) | Processes and intermediates for preparing 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine | |
| AU690165B2 (en) | Gas barrier laminate and production process thereof | |
| NO307366B1 (no) | Fremgangsmåte for fremstilling av tabletter inneholdende paroxetin og tablettformulering fremstilt ved fremgangsmåten | |
| AR242975A1 (es) | Procedimiento para preparar un pigmento de dioxido de titanio recubierto. | |
| CY2316B1 (en) | Polymorphs of donepezil hydrochloride and process for production. | |
| GB2304714B (en) | New piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them | |
| HUT74615A (en) | 2,3-cyclic-condensed-1,4-dihydro-pyridine derivatives, process for producing them and pharmaceutical compositions containing the same | |
| HUP0002270A2 (hu) | Donepezil-hidroklorid polimorf módosulatai, eljárás ezek előállítására, valamint e módosulatokat tartalmazó gyógyászati készítmények | |
| HU9401188D0 (en) | 3-quinolyl-substituted dihydropyridine derivatives, process for producing them and use of them in pharmaceutical compositions | |
| NO20002450L (no) | Sammenstilling av aktive bestanddeler, særlig tetrahydropyridiner og acetylcholinesterase-inhiberende midler, for behandling av senil demens av Alzheimer-type | |
| HU9800511D0 (en) | Process for producing 4-{4-[4-(hydroxy-diphenyl)-1-piperidinyl]-1-hydroxy-butyl}-alpha-alpha-dimethyl-phenyl-acetic.acid and phosphorylized derivatives thereof | |
| HUP9800707A3 (en) | Phenoxymethyl piperidine derivatives, process for producing them, and pharmaceutical compositions containing them | |
| WO1992005152A3 (en) | Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof | |
| AU5336990A (en) | Process for generating chloric acid and chlorine dioxide | |
| HUP0001185A3 (en) | 1-phenylalkyl-1,2,3,6-tetrahydropyridines, process for producing them and pharmaceutical compositions containing them | |
| PL303978A1 (en) | Novel derivatives of piperidine and piperazine, method of obtaining them as well as pharmaceutical preparation and method of obtaining same | |
| HUT68249A (en) | 2,6-methano-2h-quinolizin derivative as 5-ht3-receptor and pharmaceutical composition containing it and process for producing thereof | |
| NO941134D0 (no) | 1,2,5,6-tetrahydropyridin-derivat, fremgangsmåte for dets fremstilling, og dets terapeutiske anvendelser | |
| BR1100141A (pt) | Composto de 1-benzil-4-[(5,6-dimetoxi-1-indanona)-2-il]metilpiperidin a, agente inibidor de acetilcolinesterase, agente para prevenir e tratar vários tipos de demências senis e processo para produzir 1-benzil-4-[(5,6-dimetoxi-1-indanona)-2-il]metilpiperidin a | |
| ZA894469B (en) | Cholestadiene derivatives,a process for the preparation thereof,and the use thereof as pharmaceuticals acting to inhibit hmg-coa reductase |